Concepedia

Publication | Open Access

A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory <i>BRAF</i> p.V600E-Mutated Differentiated Thyroid Cancer

DOIFull Paper Access

85

Citations

22

References

2023

Year

Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud, Marie Attard, Claire Bournaud, Ludovic Lacroix, Danielle Benisvy, David Taïeb, Stéphane Bardet, Marie Terroir-Cassou-Mounat,
Clinical Cancer Research

Abstract

Dabrafenib-trametinib is effective in BRAF p.V600E-mutated DTC patients for restoring 131I uptake with PR observed 6 months after 131I administration in 38% of the patients.

References

YearCitations

Page 1